Table 2 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
Authors:
- Ezra Y. RosenEREzra Y. Rosen
- Timothy A. YapTYTimothy A. Yap
- Elisa FontanaEFElisa Fontana
- Elizabeth K. LeeELElizabeth K. Lee
- Devalingam MahalingamDMDevalingam Mahalingam
- Martin HøjgaardMHMartin Højgaard
- Niharika B. MettuNMNiharika B. Mettu
- Gregory M. CoteGCGregory M. Cote
- Ruth PlummerRPRuth Plummer
- Maria KoehlerMKMaria Koehler
- Danielle UlanetDUDanielle Ulanet
- Kezhen FeiKFKezhen Fei
Open Access
- 17 June 2026
- other
- Published by American Association for Cancer Research (AACR)